Results 41 to 50 of about 2,697 (198)
Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer [PDF]
, 2016 ACKNOWLEDGMENTS The immunohistochemistry was performed with the support of the Grampian Biorepository. GRANT SUPPORT Rebecca Swan was supported by the Jean Shanks Foundation.
Alnabulsi, Abdo +4 more
core +1 more source
Transcriptome analysis of chemically-induced sensory neuron ablation in zebrafish [PDF]
, 2016 Peripheral glia are known to have a critical role in the initial response to axon damage and degeneration. However, little is known about the cellular responses of non-myelinating glia to nerve injury.
Cox, Jane A +3 more
core +8 more sources
Exploration of Neuroprotective Therapy, 2021 The brain cholesterol content is determined by the balance between the pathways of in situ biosynthesis and cholesterol elimination via 24-hydroxylation catalyzed by cytochrome P450 46A1 (CYP46A1). Both pathways are tightly coupled and determine the rate
Irina A. Pikuleva
doaj +1 more source
Side-chain oxidized oxysterols as metabolic regulators in liver and brain [PDF]
, 2014 Oxysterols are oxygenated derivatives of cholesterol characterized by a very short half-life and their ability to pass lipophilic membranes easily, thus they are considered as important intermediates in cholesterol excretion pathways and its ...
Ali, Zeina M. F.
core +1 more source
In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds [PDF]
Journal of Medicinal Chemistry, 2019 Cytochrome P450 46A1 (CYP46A1) is a central nervous system-specific enzyme, which catalyzes cholesterol 24-hydroxylation. Currently CYP46A1 is being evaluated in a clinical trial for activation by small doses of the anti-HIV drug efavirenz. Eight efavirenz-related compounds were investigated for CYP46A1 activation in vitro, induction of a CYP46A1 ...
Natalia Mast +4 more
openaire +2 more sources
Effects of Hypercholesterolaemia in the Retina [PDF]
, 2012 © 2012 Triviño et al., licensee InTech. This is an open access chapter distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in
Gallego Collado, Beatriz Isabel +6 more
core +2 more sources
Frontiers in Pharmacology, 2022 A small dose of the anti-HIV drug efavirenz (EFV) was previously discovered to activate CYP46A1, a cholesterol-eliminating enzyme in the brain, and mitigate some of the manifestation of Alzheimer’s disease in 5XFAD mice.
Nicole El-Darzi +6 more
doaj +1 more source
Cholesterol-Metabolizing Enzyme Cytochrome P450 46A1 as a Pharmacologic Target for Alzheimer’s Disease [PDF]
, 2017 Cytochrome P450 46A1 (CYP46A1 or cholesterol 24-hydroxylase) controls cholesterol elimination from the brain and plays a role in higher order brain functions.
Arajawa, Hiroyuki +8 more
core +1 more source
Brain Sciences, 2022 Glucocorticoids are the most potent anti-inflammatory agents known. Limited in vivo data are available to characterize the mechanism underlying their cognitive side effects and transient occurrence of steroid psychosis.
Jelena Ciric +6 more
doaj +1 more source
A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat. [PDF]
EpilepsiaAbstract Soticlestat (TAK‐935) is a potent and selective inhibitor of cholesterol 24‐hydroxylase (CYP46A1), an enzyme primarily expressed in the brain that catabolizes cholesterol to 24S‐hydroxycholesterol (24HC). In the ELEKTRA phase II clinical trial, soticlestat reduced seizure frequency in patients with developmental and epileptic encephalopathies,
Kondo S +6 more
europepmc +2 more sources